Yahoo Finance Why you need to look at Silence Therapeutics' Piotroski F-Score
Silence Therapeutics (LON:SLN) is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells.
This technology might one day be worth a lot of money, but for now the group is not generating any revenue. Unfortunately, applying the Piotroski F-Score to this small cap raises some concerns... We'll get into this later, but first a quick refresher on what the F-Score means.
GET MORE DATA-DRIVEN INSIGHTS INTO LON:SLN »
The Piotroski F-Score: one indicator to rule them all?
The Piotroski F-Score is a nine-strong checklist split up into three sections, each looking at a different part of a company's financial situation. Its secret sauce is that, unlike most ratios, the F-Score looks more deeply into the direction in which a company’s financial health is moving. Keeping on top of these trends can help us stay ahead of the game.
When a stock gets beaten down it ends up in the bargain basement of the stock market. From here there are generally three outcomes. The stock either:
Stumbles along, zombie-like,
Tumbles into administration, or
Recovers emphatically
Stanford Finance Professor Joseph Piotroski wanted to sort the wheat from the chaff. After settling on the F-Score, he produced some astonishing results.
Why the F-Score does not like Silence Therapeutics
Piotroski found that weak stocks with an F-Score of 2 or less are five times more likely to either go bankrupt or delist due to financial problems. Working our way through Piotroski's checklist, we can see that Silence Therapeutics gets a lowly F-Score of 2 out of a possible 9. Food for thought for anyone looking to hold onto their money. We can see which areas of the checklist Silence Therapeutics fails in the graphic below:
Fortify your portfolio with simple, effective tools
The problem areas for Silence Therapeutics identified here can be explored in more depth on Stockopedia's research platform. All the best investors have stringent due diligence processes that reduce the chances of them suffering big losses, so why not take a leaf out of their book?
Simple tools can help us better measure and understand the risks we take. That's why the Stockopedia team has been busy building new ways of understanding investment risks and company characteristics. In this webinar, we talk about two or our most popular innovations: StockRank Styles and RiskRatings. These indicators transform a ton of vital financial information into intuitive classifications, allowing you to get an instant feel for any company on any market - sign up for a free trial to see how your stocks stack up.
